Editas Medicine Inc (EDIT)

NASDAQ HEALTHCARE
$2.76 +3.37% RSI 47 Neutral Add Alert

Moving Averages

SMA 200
$2.65
Price above

Company Profile

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Market Cap
$304.49M
P/E Ratio
None
EPS
$-1.14
Beta
2.138
Dividend Yield
0.00%
52-Week High
$4.537
52-Week Low
$1.345

Similar stocks in BIOTECHNOLOGY

BNTX
BioNTech SE
RSI 45.0
VRTX
Vertex Pharmaceuticals Inc
RSI 48.0
CRSP
CRISPR Therapeutics AG
RSI 47.0
MRNA
Moderna Inc
RSI 43.0
VKTX
Viking Therapeutics Inc
RSI 47.0
SRPT
Sarepta Therapeutics Inc
RSI 33.0
IOVA
Iovance Biotherapeutics Inc
RSI 62.0
NVAX
Novavax Inc
RSI 54.0
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 53.0
RXRX
Recursion Pharmaceuticals Inc - Class A
RSI 42.0

Data last updated: May 12, 2026 at 7:21 AM EDT

Track EDIT for free

Get e-mail RSI alerts when Editas Medicine Inc enters oversold or overbought territory. Free forever.

Add Alert